MADRID, 2 February (EUROPE PRESS) –
With the motive of the World Day against Cancer, that celebrates these Jews, Spanish experts reunited with the group OncoRetos and announced the implantation of genetic tests to detect the biomarkers, these are the causative mutations of tumors, in The National Health System (SNS).
In this sense, considering that currently, there is no respectable protocol, because access to this strategy is very disparate, leading to a loss of opportunity for patients who could not benefit from existing pharmacies in front of their treatment. washed.
Specifically, the OncoRetos group, sponsored by Luzán 5 Health Consulting, advised on the need to compete in the public system with a charter of services, dynamics and Flexible, which includes the determination of biomarkers predictive of treatment efficiency, sustainable “of the precision medicine applied to the treatment of cancer.
This reflects this group of experts in the information ‘Medicine of Precision in Oncology: an analysis of the needs and opportunities in Spain’, published recently with the collaboration of Bayer, Bristol-Myers Squibb and Roche.
Hacen is highly recommended to have a revision of the plans and initiatives at the national and international level and notes that “there is a great deal to be gained from the implantation of precision medicine applied to cancer, especially in the diagnostic camp the document.
However, the Ministry of Health announced that in September it would launch a convocation to launch the Infrastructure of Precision Medicine Associated with Science and Technology (IMPaCT). For one of the four directors of OncoRetos, Carlos Mur, said “a first step promoter” haci the Spanish Strategy of Personalized Medicine, well recognizes that “this statement of intent this much has been corrected”.
In line with this initiative of the Government, the group of experts considers that a national strategy is needed, with adequate planning and endowment of resources, “which guarantees the quality of technology, criteria of equilibrium in access to accurate medical strategies “Cancer, but also a more efficient use of the new pharmacies that work and money would have cost so much,” said the project coordinator, Joaquín Mateo.
THE STATEMENT OF ESTATAL PLAN IS A LOSS FOR PATIENTS
For his part, the director of OncoRetos, Pilar Garrido, pointed out that the launch of a state plan would be “an enormous loss of opportunity for patients”. On the other hand, it states that, if a brief statement of time is not reached, the opportunity to be positioned in the vanguard of the industrial and technological development necessary for the implementation of the medicine of medicine will be lost.
Señalan also said that, prior to the incorporation of a new pharmacy into the SNS Therapeutic Arsenal that would be linked to a biomarker patient selection test, it would need to ensure a logistics and financing plan for the implementation of health test dichos. Asi, the group’s co-director, Boi Ruiz finds “common sense” that the approval of a drug that indicates a league to a biomarker test, which includes office performance.
Nowadays, I also agree that the implementation of diagnostic tests should be carried out in accredited centers and supported by the creation of molecular assessment committees that help the interpretation of tests and the result of decision-making results.
Asimismo, Josep Tabernero, also at the front of OncoRetos, has hinted that “the funding for the implementation of the precision medicine should be associated with the needs of patients, ensuring access to tests and treatment conditions. liegar donde se reciba la sanitaria “, ha reiterado.
Mediante the adoption of these medias, creen que se podrían paliar la carencias et desigualdades que han observa in España en la implantation y en acceo a este typ de medicina. As has been observed, molecular diagnostics is not at the forefront of all hospital centers devoid of the heterogeneity of the incorporation of these techniques between hospitals. From OncoRetos notice that there is a random access to the diagnostic and, therefore, the pharmacy in the function of the place where the patient is treated.
On the other hand, critics also believe that if pharmacy approval is in line with strict quality assurance revision programs, no quality similarity processes are required for the incorporation of new drug tests and those that do not exist. a standardized procedure, without a specific regulatory mark for the evaluation, implementation or financing of biomarket testing.
To this end, the administration needs to establish a specific regulatory framework for the implementation and financing of precision medicine in Spain, which adds a majority and attention to patients and an impetus to economic crime.